Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Z M Shao

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2013
Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trialZ F Jiang, M Cristofanilli, Z M Shao, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|July 31, 2019
[Current trends of breast reconstruction after mastectomy in China: a cross-sectional study]B Q Xiu, R Guo, B L Yang, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|August 20, 2019
[Current practice of implant-based breast reconstruction: results from China national practice questionnaire survey]R Guo, B Q Xiu, Y H Su, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|October 28, 2016
[Incidental internal mammary lymph node biopsy in 113 cases of breast cancer undergoingfree abdominal flap breast reconstruction and its influencing factors]C L Quan, N S Huang, B L Yang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|December 1, 2020
[Current trend of breast cancer neoadjuvant treatment in China: a cross-sectional study]J Wang, B Q Xiu, R Guo, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|January 3, 2018
[Cost-effectiveness of multiple screening modalities on breast cancer in Chinese women from Shanghai]F Wu, M Mo, X X Qin, et al.
Cancer Chemotherapy and Pharmacology|August 21, 2012
PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapyY Z Chen, J Y Xue, C M Chen, et al.
Technology in Cancer Research & Treatment|September 15, 2012
Delineation of the cardiac substructures based on PET-CT and contrast-enhanced CT in patients with left breast cancer treated with postoperative radiotherapyX-L Yu, Q Zhang, J-Y Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancerJ Zhang, Y Lin, X J Sun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2025
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trialJ J Li, Z H Wang, L Chen, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2013
Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trialZ F Jiang, M Cristofanilli, Z M Shao, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|July 31, 2019
[Current trends of breast reconstruction after mastectomy in China: a cross-sectional study]B Q Xiu, R Guo, B L Yang, et al.
Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery]|August 20, 2019
[Current practice of implant-based breast reconstruction: results from China national practice questionnaire survey]R Guo, B Q Xiu, Y H Su, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|October 28, 2016
[Incidental internal mammary lymph node biopsy in 113 cases of breast cancer undergoingfree abdominal flap breast reconstruction and its influencing factors]C L Quan, N S Huang, B L Yang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|December 1, 2020
[Current trend of breast cancer neoadjuvant treatment in China: a cross-sectional study]J Wang, B Q Xiu, R Guo, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|January 3, 2018
[Cost-effectiveness of multiple screening modalities on breast cancer in Chinese women from Shanghai]F Wu, M Mo, X X Qin, et al.
Cancer Chemotherapy and Pharmacology|August 21, 2012
PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapyY Z Chen, J Y Xue, C M Chen, et al.
Technology in Cancer Research & Treatment|September 15, 2012
Delineation of the cardiac substructures based on PET-CT and contrast-enhanced CT in patients with left breast cancer treated with postoperative radiotherapyX-L Yu, Q Zhang, J-Y Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 16, 2018
Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancerJ Zhang, Y Lin, X J Sun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2025
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trialJ J Li, Z H Wang, L Chen, et al.
Pageof 10